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Astrocytes possess many of the same signalling molecules as neurons. However, the role of astrocytes in
information processing, if any, is unknown. Using electrophysiological and imaging methods, we report
the ﬁrst evidence that astrocytes modulate neuronal sensory inhibition in the rodent thalamus.
We found that mGlu2 receptor activity reduces inhibitory transmission from the thalamic reticular
nucleus to the somatosensory ventrobasal thalamus (VB): mIPSC frequencies in VB slices were reduced
by the Group II mGlu receptor agonist LY354740, an effect potentiated by mGlu2 positive allosteric
modulator (PAM) LY487379 co-application (30 nM LY354740: 10.0 ± 1.6% reduction; 30 nM LY354740 &
30 mM LY487379: 34.6 ± 5.2% reduction).
We then showed activation of mGlu2 receptors on astrocytes: astrocytic intracellular calcium levels
were elevated by the Group II agonist, which were further potentiated upon mGlu2 PAM co-application
(300 nM LY354740: ratio amplitude 0.016 ± 0.002; 300 nM LY354740 & 30 mM LY487379: ratio amplitude
0.035 ± 0.003).
We then demonstrated mGlu2-dependent astrocytic disinhibition of VB neurons in vivo: VB neuronal
responses to vibrissae stimulation trains were disinhibited by the Group II agonist and the mGlu2 PAM
(LY354740: 156 ± 12% of control; LY487379: 144 ± 10% of control). Presence of the glial inhibitor ﬂuo-
rocitrate abolished the mGlu2 PAM effect (91 ± 5% of control), suggesting the mGlu2 component to the
Group II effect can be attributed to activation of mGlu2 receptors localised on astrocytic processes within
the VB.
Gating of thalamocortical function via astrocyte activation represents a novel sensory processing
mechanism. As this thalamocortical circuitry is important in discriminative processes, this demonstrates
the importance of astrocytes in synaptic processes underlying attention and cognition.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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The thalamic reticular nucleus (TRN) is responsible for ensuring
synchronous activity across speciﬁc thalamo-cortical circuits
required for sensory perception or the preparation and execution of
distinct motor and/or cognitive tasks. It is therefore imperative to
ascertain how inhibition from the TRN to thalamic nuclei is
controlled to understand how neurophysiological disease states
associated with TRN malfunction precipitate (Huguenard, 1999;
Rub et al., 2003; Barbas and Zikopoulos, 2007; Pinault, 2011).
The TRN surrounds the entire anteroposterior extent of the
dorsal thalamus, meaning all thalamo-cortical and cortico-thalamic
projections must pass through andmake connections with its mesh
of inhibitory interneurons (Houser et al., 1980; Jones, 1985) (Fig. 1).
This strategic localisation between thalamus and cortex enables the
TRN to mediate coherent activity patterns within the thalamo-
cortico-thalamic excitatory loop by providing both feedback and
feedforward inhibition to thalamic nuclei upon thalamo-cortical
and cortico-thalamic input, respectively (Shosaku et al., 1989)
(Fig. 1). The Group II metabotropic glutamate (mGlu) receptors
(mGlu2/3) modulate physiologically-evoked responses in the so-
matosensory ventrobasal thalamic nucleus (VB) by reducing inhi-
bition from the TRN (Salt and Turner, 1998; Copeland et al., 2012),
with the mGlu2 component to this Group II effect likely activated
by glutamate spillover upon physiological sensory stimulation
(Copeland et al., 2012).
VB astrocytes in vitro can respond to sensory afferent stimula-
tion with an elevation in intracellular calcium (Parri et al., 2010), in
accordance with astrocytic activation in other brain regions (Porter
and McCarthy, 1996; Grosche et al., 1999; D'Ascenzo et al., 2007).
These elevations can initiate release of gliotransmitters including
glutamate (Fellin et al., 2004), D-serine (Panatier et al., 2006),
adenosine triphosphate (Guthrie et al., 1999) and adenosine
(Winder et al., 1996), with subsequent modulation of neuronal
excitability and synaptic transmission (Fellin et al., 2004; Serrano
et al., 2006). Astrocytic processes co-localise with sensory and
TRN afferent terminals around the soma and proximal dendrites of
VB neurons (Ralston, 1983; Ohara and Lieberman, 1993); thus, it is
important to understand how astrocytes are activated as concom-
itant gliotransmission may represent a signiﬁcant mechanism in
the regulation of thalamo-cortical network function via modulation
of the TRN-VB synapse.
Here, by ﬁrstly using in vitro electrophysiology we conﬁrmed
the presence of an mGlu2 component to the overall Group II mGlu
receptor effect on inhibitory synaptic transmission from the TRN toFig. 1. Thalamic circuitry underlying responses to vibrissal deﬂection. Branching
collaterals from excitatory thalamocortical and corticothalamic axons (black), which
originate from functionally linked topographical areas in the thalamus/cortex, inner-
vate the TRN (Ohara and Lieberman, 1985; Shosaku et al., 1989; Rouiller et al., 1998;
Kakei et al., 2001), and the TRN sends a reciprocal inhibitory projection (grey) back
to the thalamic area from which it receives its thalamocortical innervation (Jones,
1985; Salt, 1989; Shosaku et al., 1989; Pinault and Deschenes, 1998; Salt and Turner,
1998; Crabtree, 1999).the VB, as previously indicated in vivo (Copeland et al., 2012). By
then using in vitro calcium imaging, which enabled the identiﬁca-
tion of the cellular foundation supporting this mechanism, the
mGlu2 component was identiﬁed as astrocyte-dependent: mGlu2
receptor activation elicited elevations in astrocytic (but not
neuronal) intracellular calcium - a novel mechanism of astrocyte
activation. Finally, we identiﬁed VB neurons responsive to trains of
single vibrissa stimuli in vivo and applied selective compounds
locally. We delineate that the mGlu2 receptor astrocyte-dependent
mechanism contributes to the modulation of sensory transmission
in a physiological context. Together, the data indicate that the
mGlu2 component to the Group II mGlu receptor effect is purely
astrocyte-dependent, making astrocytes an integral signalling
intermediary in sensory processing.
2. Material and methods
2.1. Ethical approval
All experimental conditions and procedures were either in
accordance with the National Institutes of Health (NIH) regulations
of animal care covered in the Principles of Laboratory Animal Care,
NIH publication 85e23, revised 1985, and were approved by the Eli
Lilly and Company Institutional Animal Care and Use Committee, or
were approved by the Home Ofﬁce (UK) and were in accordance
with the UK Animals (Scientiﬁc Procedures) Act 1986 and associ-
ated guidelines.
2.2. In vitro electrophysiology
2.2.1. Animals
Male Sprague-Dawley rats (12e18 days old; Harlan, Indian-
apolis, USA, n¼ 10) were deeply anaesthetised with 4.0% isoﬂurane
and decapitated into a container of crushed ice.
2.2.2. Slice preparation and maintaining solutions
The brainwas quickly removed and placed in an oxygenated, ice
cold beaker of slicing solution which contained (in mM): 110 NaCl;
10 MgCl2; 2 KCl; 26 NaHCO3; 1.25 NaH2PO4; 0.5 CaCl2; 10 HEPES
and 15 glucose (pH adjusted to 7.45 with NaOH, osmolarity was
308e312 mOsm). After cooling in slicing solution for 2e3 min, the
whole brain was blocked (portions of anterior and posterior tissue
removed) using a razor blade and then glued to the microslicer
(DTK Zero 1, DSK) tray using cyanoacrylate. The tray containing the
blocked and mounted brain was ﬁlled with oxygenated, ice cold
slicing solution and serial, coronal sections were cut at a thickness
of 300 mm. Slices were then placed in a larger recovery chamber
containing oxygenated slicing solution at room temperature
(18e20 C). The recovery chamber was in a large water bath, which
was initially at room temperature. After a 10 min period, 500 mL of
0.5 M CaCl2 solution was slowly added to the recovery chamber
(500 ml volume) to increase the calcium concentration to 1 mM.
The water bath was then turned on and the temperature was
monitored inside the recovery chamber. The recovery chamber
temperature was allowed to reach 33e34 C for a period of
approximately 30 min, after which the water bath was turned off
and the recovery chamber was allowed to slowly return to room
temperature (18e20 C). Slices were used for recording after at
least 1 h of recovery time.
2.2.3. Recording conditions
Slices were placed in a superfusion chamber mounted on a
Nikon Eclipse FN-1 microscope. Neurons within the VB area of the
thalamus were visualized using IR/DIC water immersion optics. The
recording solution was composed of (in mM): 115 NaCl; 1.5 MgCl2;
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at pH 7.45, oxygenated with carbogen gas (95%O2/5%CO2) and os-
molarity of 300e305 mOsm. The brain slice in the chamber was
continually superfused at a rate of 3 mL/min with oxygenated
recording solution (18e20 C). Compound containing solutions
were applied to the slice via whole chamber superfusion. Glass
recording electrodes were ﬁlled with (in mM): 140 CsCl; 1 MgCl2;
10 HEPES; 3 NaATP; 0.3 NaGTP; 1 Cs-EGTA at pH 7.2 and osmolarity
adjusted to 294e300 mOsm and had a resistance of 2e4 MU.
2.2.4. Experimental protocol
Visualized neurons were patch clamped in whole cell conﬁgu-
ration (Multiclamp 700B, MDS) and access resistance (Ra) was
evaluated in voltage clampmode. A gapfree protocol (Clampex V10,
MDS) with a holding potential of 70 mV was used to record
miniature synaptic events until the access resistance and holding
current were stable in recording solution only. The slice was then
superfused with recording solution containing 10 mM 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX; Tocris), 50 mM DL-2-Amino-5-
phosphonopentanoic acid (DL-APV; Tocris) and 0.5 mM tetrodo-
toxin (TTX; Abcam) to block the AMPA- and NMDA-evoked mini-
ature and large amplitude events due to direct action potential
ﬁring of inhibitory neurons, respectively, leaving only the GABA
mediated miniature synaptic events (conﬁrmed in preliminary
experiments by complete blockade of remaining synaptic events
with 10 mM bicuculline). LY354740, LY341495 and LY487379 (all
made in-house) stocks were made in 100% DMSO at 1000 the
desired working concentration. Compounds were diluted into the
recording solution containing CNQX, APV and TTX immediately
before application to the brain slice. All solutions applied to the
brain slices contained 0.1%e0.2% DMSO. DMSO content was
matched between solutions for each experimental protocol. Com-
pound treatment periods were from 10 to 12 min in duration.
2.2.5. Data collection and statistical analysis
The frequency of the GABAergic miniature synaptic events was
determined during the ﬁnal 5 min of each treatment period
(baseline, 30 nM LY354740, 100 nM LY354740, 100 nM
LY354740þ 100 nM LY341495, 30 nM LY354740þ 30 mMLY487379,
and 30 mM LY478379) using the MiniAnalysis program (V6.0.4,
Synaptosoft). Inter-event intervals were calculated and plotted as
cumulative fraction histograms for each treatment group. The
Kolmogorov-Smirnov test was performed on the inter-event in-
terval cumulative fractions to determine statistical signiﬁcance of
compound effects on spontaneous GABAergic synaptic event
activity.
2.3. Intracellular calcium imaging
2.3.1. Animals
Male juvenile Wistar rats and mice (10e16 days old; n ¼ 5; bred
in house) were killed by halothane overdose followed by cervical
dislocation. IP3 R2 Knockout Mice (Ju Chen, UCSD) were bred from
founder mice kindly obtained from A. Araque, Instituto Cajal,
Madrid. Mice were bred on a C57Bl6 background. WTs (-/-) were
bred from Heterozygous (±) bred pairs. Genotyping was conducted
by Transnetyx (Cordova, TN, USA).
2.3.2. Slice preparation and maintaining solutions
Slices were prepared as described previously (Parri and Crunelli,
2001). Brieﬂy, following removal from the skull, the brainwas glued
with cyanoacrylate adhesive to a metal block and submerged in the
bath of Microm MV (Zeiss, Welwyn Garden City, UK) tissue slicer.
The bathing solution was of the following composition (in mM):
NaCl 120, NaHCO3 16, KCl 1, KH2PO4 1.25, MgSO4 5, CaCl2 1, glucose10, and was maintained at 5 C. Thalamic slices (350 mm) were cut
in the horizontal plane, and then stored in a 95% O2/5% CO2 bubbled
solution of identical composition at room temperature.
Following a 1 h recovery period, experiments were performed in
a solution of the following composition (in mM): NaCl 120, NaHCO3
16 or 25, KCl 2, KH2PO4 1.25, MgSO4 1, CaCl2 2, glucose 10, at room
temperature (20e24 C), unless otherwise stated. TTX (0.5 mm) was
included in the perfusate to block sodium currents in VB neurons
(Parri and Crunelli, 1998). Compounds LY354740, LY487379 and
MPEPwere obtained from Tocris (Bristol, UK), Suramin from Sigma-
Aldrich.2.3.3. Fluorescence imaging
Slices were loaded with either Fura-2 or Fluo4-AM (Invitrogen)
dye (5 mM with 0.01% pluronic acid) after a post-cutting recovery
period of 1 h. Fluo4 was routinely used in experiments to monitor
Group II mGlu receptor activation, Fura-2 was used in dose
response determination experiments where comparison of repet-
itive drug applications in the same astrocytes was required. As-
trocytes and neurons were distinguishable by their morphological
proﬁles: VB neurons have large somas (18 mm diameter), with 3e4
dendrites; astrocytes have much smaller somas (~8 mm) with
nebulous processes (Parri et al., 2001). Slices were also loaded with
1 mM Sulforhodamine 101 (SR101), according to published in vitro
methods (Kaﬁtz et al., 2008) for veriﬁcation of astrocyte identity.
The recording chamber and manipulators were mounted on a
motorized moveable bridge (Luigs and Neumann) and ﬂuorescence
dyes were excited using an Optoscan monochromator system,
ﬁtted to a Nikon FN1 upright microscope; ﬁlter cubes for selective
Fura-2, Fluo4 and SR101 imaging were obtained from Chroma.
Images of slice areas of 444 mm  341 mmwere routinely acquired
every 5s with a20 objective lens (NA¼ 0.8) using an ORCA ERCCD
camera (Hamamatsu) and analysed using Simple PCI software
(Hamamatsu). Fluorescence values over time for speciﬁc regions of
interest (ROIs) were exported and analysed using Sigmaplot
(Systat). The number of events during a recording was determined
by identifying events where amplitude exceeded 2 standard de-
viations of baseline variations. For determination of amplitude
changes, the absolute ratio or DF increases in the different condi-
tions in the same cells were directly compared, so providing an
internal control.2.3.4. Statistical analysis
All quantitative data are expressed in the text as mean (±SEM).
Statistical tests included Student's t-test and the Kolmogor-
oveSmirnov test for cumulative population distributions, as
indicated.2.4. In vivo single neuron recording and iontophoresis
2.4.1. Animals
All experiments were conducted using adult male Wistar rats
(340e540 g, n ¼ 18). Animals (Harlan, UK) were housed on a 12 h
light/dark cycle with food and water ad libitum.2.4.2. Surgery
Animals were anaesthetised with urethane (1.2 g/kg intraper-
itoneal [i.p.] injection) and were prepared for recording as previ-
ously described (Salt, 1987, 1989). Throughout the experiments,
electroencephalogram and electrocardiogram were monitored.
Additional urethane anaesthetic was administered i. p. as required,
and the experiment was terminated with an overdose of the same
anaesthetic.
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Seven-barrel recording and iontophoretic glass pipettes were
advanced into the VB. Extracellular recordings were made from
single VB neurons responsive to somatosensory input through the
central barrel (ﬁlled with 4 M sodium chloride [NaCl]). Iontopho-
retic drug applications were performed using the outer barrels
(Salt, 1987, 1989). On each occasion, one of the outer barrels was
ﬁlled with 1 M NaCl for current balancing. The remaining outer
barrels each contained one of the following substances: N-methyl-
D-aspartate (NMDA; 50 mM, pH8.0 in 150 mM NaCl), (1S,2S,5R,6S)-
2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740;
5 mM, pH8.0 in 75 mMNaCl), DL-Fluorocitric Acid (10 mM, pH8.0 in
75 nM NaCl) as Naþ salts, ejected as anions, with 2,2,2-Triﬂuoro-N-
[4-(2-methoxyphenoxy)phenyl]-N-(3-pyridinylmethyl)ethane-
sulfonamide hydrochloride (LY487379; 1 mM, pH6.0, in 1%
dimethyl sulfoxide [DMSO], 75 mM NaCl ejected as cations. All
compounds were prevented from diffusing out of the pipette by
using a retaining current (10e20 nA) of opposite polarity to that of
the ejection current. Compounds were ejected within a current
range ensured to produce a sub-maximal effect on sensory inhi-
bition (LY354740 6nA-50nA; LY487379 50nA-100nA) or neuronal
excitation (NMDA 35nA-85nA). Fluorocitrate was obtained from
Sigma (St Louis, MO, USA), with all other compounds obtained from
Tocris (Bristol, UK). It is of importance to note that both the Group II
orthosteric agonist LY354740 (Monn et al., 1997) and the mGlu2
positive allosteric modulator (PAM) LY487379 (Schaffhauser et al.,
2003) used in this study possess a higher selectivity for their re-
ceptor targets than the prototypical Group II orthosteric antagonist
(2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl)
propanoic acid (LY341495) (Kingston et al., 1998), which has been
demonstrated to have antagonistic properties at both the Group II
and Group III mGlu receptors in a similar iontophoretic in vivo study
(Cirone and Salt, 2001).
2.4.4. Stimulation protocols
Neurons were identiﬁed as VB neurons on the basis of stereo-
taxic location (Paxinos andWatson, 1998) and responses to vibrissa
deﬂection. Vibrissa deﬂection was performed using ﬁne air-jets
directed through 23 gauge needles mounted on micro-
manipulators positioned and orientated close to the vibrissa to
ensure deﬂection of a single vibrissa was achieved. Air-jets were
electronically gated with solenoid valves that produced a rising air
pulse at the vibrissa 8 ms after switching. Response latencies were
calculated from the start of the gating pulse. Using such an
approach it is possible to use air-jets to evoke an excitatory
response from stimulation of a single vibrissa, as described previ-
ously (Salt,1989). Prior to the beginning of each of the experimental
protocols described below, the ‘principal’ vibrissa (i.e. the vibrissa
at the centre of the receptive ﬁeld) for each neuron was identiﬁed.
All neurons recorded from were quiescent.
2.4.4.1. Protocol 1. The effects of the selective glial inhibitor ﬂuo-
rocitrate on VB neuronal responses to train stimulation of vibrissae
and iontophoretic NMDA application.
Cycles of sensory and NMDA stimulation were established and
repeated continuously whilst recording from neurons. Cycles (60s
long) contained two types of stimuli consisting of 500e1000ms
duration trains (5e10 Hz) of air-jets directed at the principal
vibrissa, repeated 4 times with a 4s interstimulus interval, followed
by a single iontophoretic NMDA application (10s), which was timed
to provide a 15s interval either side of the sensory stimulations.
After several control cycles displaying consistent VB neuronal re-
sponses had been recorded, ﬂuorocitrate was iontophoretically
ejected for 5e12min as required until a consistent effect of ﬂuo-
rocitrate was observed. An inter-stimulus interval of 4s is sufﬁcientto ensure that any post-stimulus effects from either stimulus type
are no longer apparent upon subsequent stimulation (Salt, 1989;
Turner and Salt, 2003).
2.4.4.2. Protocol 2. The effects of the selective glial inhibitor ﬂuo-
rocitrate on Group II mGlu receptor modulation of sensory
inhibition.
Cycles of sensory stimulation (10s long) were established and
repeated continuously whilst recording from neurons. Cycles con-
tained one type of stimulus consisting of 500e1000ms duration
trains (5e10 Hz) of air-jets directed at the principal vibrissa. After
several control cycles displaying consistent neuronal responses had
been recorded, LY487379 and LY354740 were iontophoretically
ejected for 2e15 min s as required, under normal conditions and in
the presence of ﬂuorocitrate. After cessation of compound ejection,
sensory stimulation cycles were continued until VB neuronal re-
sponses had returned to their respective control levels.
2.4.5. Data collection and statistical analysis
Throughout the study, extracellular single neuron action po-
tentials were gated, timed and counted using a window discrimi-
nator, a CED1401 interface and Spike2 software (Cambridge
Electronic Design, Cambridge, UK), which recorded the output from
the iontophoresis unit and also triggered the iontophoretic and
sensory stimuli sequences. Data were analysed by plotting post-
stimulus time histograms (PSTHs) from these recordings by
counting the spikes evoked by either NMDA ejection or sensory
stimulation. Data are expressed as a percentage of control re-
sponses prior to compound application (±SEM). Comparisons were
made using Wilcoxon matched-pairs test (p < 0.05).
3. Results
The pharmacological compounds used in this study are clearly
crucial to the interpretation of the results. LY354740 is the best-
studied selective Group II orthosteric agonist (Monn et al., 1997;
Schoepp et al., 2003), and has been used extensively to reveal
Group II mGlu receptor function in both behavioural (Schoepp et al.,
2003; Nordquist et al., 2008) and in vitro/vivo physiological (Flor
et al., 2002; Moldrich et al., 2003; Copeland et al., 2012) assays in
rodent and human CNS models. LY487379 is a highly selective
mGlu2 PAM, which possesses no intrinsic agonist activity but does
enhance responses to submaximal glutamate without activity at
other receptors or ion channels (Johnson et al., 2003). LY487379 has
been used in a number of pharmacological assays, including
behavioural and in vitro/vivo electrophysiological studies in the
rodent CNS (Schaffhauser et al., 2003; Galici et al., 2005; Poisik
et al., 2005; Harich et al., 2007; Hermes and Renaud, 2011;
Nikiforuk et al., 2010; Copeland et al., 2012). The orthosteric
antagonist LY341495 has a relatively high selectivity with a nano-
molar potency for Group II mGlu receptor, with submicromolar
potencies at all other mGlu receptor subtypes (Kingston et al., 1998;
Schoepp et al., 1999). However, the parameters used for LY341495
in this study have been demonstrated previously to produce se-
lective antagonism for the Group II mGlu receptors (Kingston et al.,
1998).
3.1. mGlu2 receptors modulate synaptic transmission at the TRN-VB
synapse
Group II mGlu receptor activation has been previously demon-
strated to depress VB neuron inhibitory postsynaptic potentials
(IPSPs) evoked upon stimulation of the TRN (Turner and Salt, 2003),
and an mGlu2 component to this Group II effect was recently
described in an in vivo study (Copeland et al., 2012). Therefore, we
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modulate inhibitory synaptic transmission at the TRN-VB synapse.
One component that would contribute to IPSP depression is direct
inhibition of GABAergic vesicle fusion with the presynaptic TRN
membrane. By recording miniature inhibitory postsynaptic cur-
rents (mIPSCs) it is possible to examine the frequency of sponta-
neous presynaptic quantal release events and so detect changes in
transmitter release in the absence of evoked synaptic activity. In the
absence of endogenous mGlu2 receptor activation, a sub-maximal
concentration (30 nM) of the Group II agonist LY354740 was able
to reduce mIPSC frequency compared to baseline when applied
alone (10.0 ± 1.6% reduction compared to control, n ¼ 6 from 6
slices, Fig. 2). Application of themGlu2 PAM LY487379 alone had no
effect on mIPSC frequency (data not shown). By nature of design,
PAMs potentiate the action of orthosteric agonists, without them-
selves possessing any intrinsic agonist activity (Johnson et al.,
2003). This lack of effect of the PAM in this preparation is there-
fore unsurprising as there is likely no baseline activation of mGlu2
receptors under these conditions. However, when the mGlu2 PAM
was co-applied with the sub-maximal concentration of Group II
agonist, a signiﬁcant additional reduction in mIPSC frequency was
observed (30 nM LY354740 & 30 mM LY487379: 34.6 ± 5.2%Fig. 2. The Group II mGlu receptor effect on spontaneous presynaptic quantal release ev
and VB with recording site indicated. b Effects of the Group II agonist LY354740 (30 nM) a
spontaneous mIPSC events (ﬁnal 5 min bin) in the VB. Speciﬁcity of the Group II agonist effe
Traces from individual neurons illustrating the mean responses of neurons to the same con
the cumulative fraction of the calculated inter-event intervals of the spontaneous mIPSCs ireduction, n ¼ 6 from 6 slices, p < 0.001, Fig. 2), comparable to that
seen upon maximal agonist effect (100 nM LY354740: 39.1 ± 4.7%
reduction compared to control, n ¼ 6 from 6 slices, p < 0.001;
Fig. 2). The Group II mGlu receptor effect on mIPSC frequency was
conﬁrmed by its reversal upon Group II orthosteric antagonist
LY341495 co-application (100 nM LY354740 & 100 nM LY341495:
6.6 ± 7.5% reduction in mIPSC frequency compared to control, n ¼ 6
from 6 slices, p < 0.01, Fig. 2). Taken together these data indicate
that there is indeed an mGlu2 component to the Group II mGlu
receptor effect on GABAergic transmission at the TRN-VB synapse.
Ultrastructural studies indicate that TRN terminals exclusively ex-
press the mGlu3 receptor subtype (Tamaru et al., 2001), while VB
astrocytes express both mGlu2 and mGlu3 (Ralston, 1983; Ohara
and Lieberman, 1993; Liu et al., 1998; Mineff and Valtschanoff,
1999). We therefore sought to conﬁrm functional expression of
astrocytic mGlu2 receptors.3.2. mGlu2 receptors activate astrocytes in the VB
Are mGlu2 receptors themselves able to directly activate as-
trocytes? To address this question, we monitored intracellular
calcium levels in both VB neurons and astrocytes in an acute in vitroents includes an mGlu2 receptor-mediated component. a Circuitry between the TRN
lone or in conjunction with the mGlu2 PAM LY487379 (30ìM) on the total number of
ct was conﬁrmed upon its reversal using the Group II antagonist LY341495 (100 nM). c
ditions as described in b. d Effects of the same compound application combinations on
n the VB. **p < 0.001; ***p < 0.0001; Glu e glutamate.
C.S. Copeland et al. / Neuropharmacology 121 (2017) 100e110 105thalamic slice preparation. In the presence of TTX to block neuronal
activity, a sub-maximal concentration of the Group II orthosteric
agonist induced increases in intracellular calcium levels compared
to baseline when applied alone (300 nM, ratio amplitude
0.016 ± 0.002, n ¼ 56 astrocytes from 5 slices, Fig. 3aec). Applica-
tion of the mGlu2 PAM alone had no effect on intracellular calcium
levels (data not shown). Upon co-application of the mGlu2 PAM
with the agonist there was a signiﬁcant potentiation in astrocytic
intracellular calcium levels in the same astrocytes (300 nM
LY354740 plus 30 mM LY487379, ratio amplitude 0.035 ± 0.003,
n ¼ 56 astrocytes from 5 slices, p < 0.001; Fig. 3aec). This Group II
mGlu receptor effect could be reversed upon co-application of 1 mM
of the Group II antagonist LY341495 (1 mM LY354740, 2.11 ± 0.45 DF
% change; 1 mM LY354740 plus 1 mM LY341495, 0.28 ± 0.17DF%Fig. 3. mGlu2 receptor activation can elicit increases in astrocytic intracellular calcium l
astrocyte differentiation. Identiﬁed astrocytes and neurons are indicated. b Traces displaying
increasing concentrations of the Group II agonist LY354740 either alone or in conjunctionwit
a neuron. c Bargraphs summarise results from a number of experiments corresponding to the
30 mM LY487379, 3 slices, n ¼ 21; 300 nM LY354740 alone and co-applied with 30 mM LY4
slices, n ¼ 49; Neuron: 1 mM LY354740 alone and co-applied with 30 mM LY487379, 3 sli
(LY4872379) bars. d Bargraphs summarise results from a number of experiments demonst
changes in calcium ﬂuorescence upon application of 1 mM of the Group II agonist LY354740 a
the right display €AF% changes in calcium ﬂuorescence upon application of 1 mM of the Group
Upper traces display ﬂuorescence over time for four example astrocytes from a slice from a
(100 mM). Traces below show responses from astrocytes in a slice from an IP3R2(-/-) knock
d represent the mean % response (±SEM) of the ﬂuorescence, **p < 0.01, ***p < 0.001.change, n ¼ 10 astrocytes from 5 slices, p < 0.01; Fig. 3d). Co-
application of the Group II agonist with 5 mM 2-Methyl-6-(phe-
nylethynyl)pyridine (MPEP) and 100 mM suramin had no effect
(1 mM LY354740 alone, 3.14 ± 0.30 DF% change; 1 mM LY354740 plus
5 mM MPEP and 100 mM suramin, 2.96 ± 0.30 DF% change, n ¼ 106
astrocytes from 4 slices; Fig. 3d), ruling out any mGlu5 or purine
receptor involvement. Furthermore, there was no change in the
intracellular calcium levels in neurons in the same slices when a
maximal concentration of the Group II orthosteric agonist was
applied alone (1 mM, ratio amplitude 0.004 ± 0.006, n¼ 36 neurons
from 3 slices; Fig. 3aec) nor when co-applied in the same slices
with the mGlu2 PAM (1 mM LY354740 plus 30 mM LY487379, ratio
change 0.005 ± 0.003, n ¼ 36 neurons from 3 slices, p > 0.05;
Fig. 3aec). Gq-protein coupled receptor-dependent calcium ﬂuxesevels. a Images from a slice loaded with Fluo-4-AM for calcium imaging, and SR101 for
transient intracellular calcium elevations in an astrocyte in response to application of
h the mGlu2 PAM LY487379. Two traces on the right display ratio over time for example
illustrative traces above in b. (Astrocytes: 100 nM LY354740 alone and co-applied with
87379, 5 slices, n ¼ 56; 1 mM LY354740 alone and co-applied with 30 mM LY487379, 3
ces, n ¼ 36). Compound application is indicated by the striped (LY354740) and grey
rating antagonism of the Group II agonist effect. The two bars on the left display €AF%
lone and in conjunction with 1 mM of the Group II antagonist LY341495. The two bars on
II agonist LY354740 alone and in conjunction with 5 mM MPEP and 100 mM suramin. e
wild-type (IP3R2þ/þ) mouse with responses to Group II agonist (1 mM) and glutamate
-out mouse. Bargraphs to the right summarise a number of experiments. Bars in c and
Fig. 4. Astrocyte inactivation attenuates the maintained component of VB neuron
responses without affecting responses to NMDA. a Circuitry between the TRN and VB
with recording site indicated. b Raster displays and peristimulus time histograms
(PSTHs) of responses of a VB neuron (CVB142c) to either train stimulation of a single
vibrissa (50 ms bins, 8 trials) or iontophoretic application of NMDA (15 nA; 1s bins, 2
trials) under normal conditions and in the presence of ﬂuorocitrate (20 nA; 5 min). c
Bars represent the mean % response (±SEM) under normal conditions (100%) and in
the presence of ﬂuorocitrate to train stimulation (total, initial and maintained) of single
vibrissae (n ¼ 16) and NMDA (n ¼ 11). ***p < 0.001.
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(IP3R) activation resulting in the release of endoplasmic reticulum
calcium ions into the cytosol (Sharp et al., 1999; Holtzclaw et al.,
2002; Hertle and Yeckel, 2007; Petravicz et al., 2008). Astrocytes
predominantly express the IP3R2 subtype (Petravicz et al., 2008).
We therefore tested the effects of the mGlu2 agonist on acute slices
from IP3R2 -/- knockout mice. A maximal concentration (1 mM) of
the orthosteric agonist LY354740 was applied to Fluo-4 loaded
slices fromwild-type (IP3R2þ/þ) and knock-out (IP3R2-/-) mice. A
maximal concentration of glutamate (100 mM) that also activates
other calcium signalling pathways such as ionotropic receptors was
subsequently applied to the same slice to provide an internal
control. In slices from wild-type animals, both LY354740 and
glutamate elicited robust astrocyte calcium elevations (LY354740:
5.12 ± 0.65%, Glutamate 7.41 ± 0.60, n ¼ 188 astrocytes, 6 slices).
However in slices from knock-out mice, while glutamate elicited
calcium elevations (5.60 ± 0.35%), responses to LY354730 were
abrogated (1.05 ± 0.18%, n ¼ 100 astrocytes from 5 slices Fig. 3e).
The initial Ca2þ peak induced by glutamate is abolished in the IP3R2
knock-out preparation, and can likely be attributed to Group I
mGluR activation, whose signal transduction pathway is mediated
via Gq. The remaining glutamate effect in the IP3R2 knock-out
preparation can be attributed largely to activation of ionotropic
glutamate receptors (H€oft et al., 2014), as application of ionotropic
glutamate receptor antagonists (NBQX and D-AP5) reduced the
calcium associated ﬂuorescence by 79% (data not shown); whilst
the initial Ca2þ peak, abolished, and this can likely be attributed to
Group I mGluR activation. Together, these data show that mGlu2
receptors elicit functional astrocyte responses via IP3R2 mediated
calcium release; an effect traditionally associated with Gq/11
coupled metabotropic receptors, as opposed to the Gi/o coupled
mGlu2 receptor. However, the same metabotropic receptor, when
expressed in different cell types/brain areas, is able to couple with
alternate G-proteins: GABAB receptors have been reported to
couple to both Gi/o and Gq (Gould et al., 2014; Mariotti et al., 2016)
and D1 receptors to Gs, Golf and Gq proteins (Lee et al., 2004).
Furthermore, GABAB receptor activation, usually assumed to be
coupled via Gi/o, induces calcium elevations in VB thalamus (Gould
et al., 2014). As well as conﬁrming an astrocytic locus for thalamic
mGlu2 action, this represents a novel mechanism of astrocytic
activation.
3.3. Astrocytes gate neuronal responses to somatosensory
stimulation
Does this mechanism modulate thalamocortical responses to
sensory stimulation in an in vivo system (Fig. 4a)? To test this
question, we ﬁrst assessed whether astrocytes contribute to the
generation of VB neuron responses to physiological somatosensory
stimulation. A recording electrode with iontophoretic capabilities
was advanced into the VB of rats, and vibrissae were deﬂected as
required to generate physiologically relevant activity. Observed
waveforms were similar to those previously published (Salt, 1989),
and were not perturbed under experimental conditions. Fluoroci-
trate selectively inhibits glia by interfering with the astrocytic
tricarboxylic acid cycle (Fonnum et al., 1997), which is used to
generate energy in the form of guanosine triphosphate (GTP). Upon
local application of ﬂuorocitrate, a reduction in neuronal responses
to repetitive 10 Hz stimulation (1s duration) of the principal
vibrissae was observed. Speciﬁcally, the maintained component of
the neuronal response proﬁle was signiﬁcantly reduced (68 ± 4% of
control, n ¼ 16 from 9 rats, p < 0.001), whereas the initial
component remained unaffected (101 ± 3% of control, n¼ 16 from 9
rats, p > 0.05) (Fig. 4b,c). The maintained component of neuronal
responses to vibrissa stimulation comprises an NMDA-mediatedcontribution under normal physiological conditions (Salt, 1986).
However, neuronal responses to exogenous NMDA application
were unaffected in the presence of ﬂuorocitrate (102 ± 4% of con-
trol, n ¼ 11 from 5 rats, p > 0.05) (Fig. 4b right panels; Fig. 4c), thus
indicating that inhibition of astrocyte function does not impact
directly on NMDA receptor responses or upon post-synaptic
neuronal excitability. Furthermore, as the initial component of
neuronal responses to vibrissa stimulation was reliably present
upon each stimulus presentation (see raster plot in Fig. 4b) the
impact of ﬂuorocitrate on neurotransmitter release can be consid-
ered minimal. The reduction of the maintained neuronal response
component to vibrissae stimulation observed in the presence of
ﬂuorocitrate could therefore be attributable to the attenuation of an
astrocytic mechanism of synaptic modulation independent of a
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3.4. mGlu2 receptors modulate synaptic transmission at the TRN-
VB synapse via an astrocyte-dependent mechanism
Consistent with previous ﬁndings (Copeland et al., 2012), local
application of both the Group II orthosteric agonist LY354740 and
the mGlu2 PAM LY487379 were able to signiﬁcantly increase
neuronal responses to 10 Hz train stimulation of principal vibrissae
under normal conditions (LY354740: 156 ± 12% of control, n ¼ 6
from 4 rats, p < 0.05; LY487379: 144 ± 10% of control, n ¼ 6 from 6
rats, p < 0.05; Fig. 5a). However, in the same population of neurons
in the presence of ﬂuorocitrate, the effect of the mGlu2 PAM was
completely abolished (91 ± 5% of ﬂuorocitrate control, n ¼ 6 from 4
rats, p > 0.05; Fig. 5b) whereas the Group II mGlu receptor
orthosteric agonist effect remained (156 ± 9% of ﬂuorocitrate con-
trol, n ¼ 6 from 6 rats, p < 0.05; Fig. 5b). Fluorocitrate inhibits
formation of the energy source GTP (Fonnum et al., 1997), which is
required for mGlu2 receptor signal transduction (Niswender and
Conn, 2010). From this selective attenuation of the mGlu2 PAM
effect upon inhibition of astrocyte functionwe can infer that mGlu2
receptor modulation of the TRN-VB synapse function is astrocyte-
dependent. Furthermore, we can attribute the remaining Group II
mGlu receptor orthosteric agonist effect to activation of neuronal
mGlu3 receptors localised on presynaptic TRN terminals (Tamaru
et al., 2001; Turner and Salt, 2003). Thus we have now shown
that mGlu2 receptor-mediated effects upon somatosensory trans-
missionwithin the VB are astrocyte dependent under physiological
conditions.
4. Discussion
By using selective pharmacological tools in complementary
in vitro and in vivo preparations we have been able to identify a
novel mechanism of mGlu2 receptor-mediated astrocytic activa-
tion. In summary, our in vitro experiments showed that selective
potentiation of mGlu2 receptor activity contributes to reducingFig. 5. Astrocyte inactivation attenuates the mGlu2 component of the Group II effect on
(CVB138a) to train stimulation (50 ms bins, 6 trials) of a single vibrissa under normal condit
iontophoretic application of either LY487379 (50 nA, 2 min) or LY354740 (50 nA, 2 min), and
plots. b Bars represent the mean % of control (±SEM) of responses to train stimulation of
conditions and in the presence of ﬂuorocitrate. *p < 0.05.inhibitory transmission at the TRN-VB synapse, and delineate the
anatomical localisation of these mGlu2 receptors to astrocytes,
whose processes are known to co-localise with TRN terminals on
the soma and/or proximal dendrites of VB neurons (Ralston, 1983;
Ohara and Lieberman,1993) (Fig. 6). Our in vivo experiments extend
our in vitro ﬁndings, showing that selective potentiation of mGlu2
receptor activity leads to an astrocyte-dependent increase in VB
neuron responsiveness to somatosensory stimulation in a physio-
logical context. This mechanism likely occurs upon physiological
sensory stimulation as previously described, with the source of
endogenous glutamate being glutamate spillover from the sensory
afferent terminals activating mGlu2 receptors localised on the glial
processes (Copeland et al., 2012). Therefore, we provide the ﬁrst
evidence that physiological activation of astrocytic mGlu2 re-
ceptors leads to concomitant modulation of thalamic processing of
sensory inputs. Furthermore, previously the mGlu3 and mGlu5
receptor subtypes have been shown to be expressed in astrocytes
(Niswender and Conn, 2010), with the mGlu5 subtype shown to
mediate sensory driven activation of thalamic astrocytes (Parri
et al., 2010). We have now shown functional astrocytic mGlu2 re-
ceptors are also able to elicit an increase in astrocytic intracellular
calcium levels.
Whilst it has been previously demonstrated that astrocytes can
act as a primary source of glutamate (Parri et al., 2001), we have
now shown for the ﬁrst time that astrocytes can themselves be
activated via mGlu2 receptors. The functional outcome of this
mechanism facilitates disinhibition of the postsynaptic VB neuron
via action at the presynaptic TRN bouton, thus increasing the
responsivity of the VB neuron to sensory stimulation, as opposed to
providing a direct postsynaptic excitatory innervation (Parri et al.,
2001). We are able to delineate this by drawing together results
from different experimental paradigms. Firstly, neither the selec-
tive glial inhibitor ﬂuorocitrate nor the Group II orthosteric agonist
or mGlu2 PAM perturbed VB neuronal responses to exogenous
NMDA (Copeland et al., 2012), indicating that neither normal
astrocytic function nor Group II/mGlu2 receptor activation directly
impinges upon the postsynaptic excitability of the VB neuron. Thesensory inhibition in the VB. a Raster displays and PSTHs of responses of a VB neuron
ions and in the presence of ﬂuorocitrate (20 nA; 10 min) during a control period, upon
during recovery. Abscissa indicated on the bottom left raster and PSTH plot applies to all
single vibrissae (n ¼ 6) to application of either LY487379 or LY354740 under normal
Fig 6. Summary diagram of Group II mGlu receptor localizations in the VB, and
their effects upon synaptic transmission. Using selective pharmacological com-
pounds, we have been able to show that mGlu2 receptors are likely located on
astrocytic processes surrounding the TRN-VB synapse, whilst mGlu3 receptors are
likely located on the TRN terminals themselves in the VB. Activation of astrocytic
mGlu2 receptors likely facilitates elevations in intracellular calcium levels (indicated
by a green plus), which may lead to presynaptic modulation of the TRN-VB synapse,
whilst neuronal mGlu3 receptor activation is thought to decrease GABAergic trans-
mission (indicated by the red minus signs). Both of the Group II mGlu receptor sub-
types are likely activated via glutamate spillover from the synapse formed between the
sensory afferent and the VB proximal dendrite upon physiological sensory stimulation
(Copeland et al., 2012). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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ment of somatodendritically expressed mGlu2 receptors
(Watanabe and Nakanishi, 2003), which corresponds with ultra-
structural evidence indicating a lack of Group II mGlu receptor
expression by sensory thalamic neurons (Alexander and Godwin,
2006). Furthermore, Group II mGlu receptor activation reduces
IPSPs evoked in VB neurons upon stimulation of the TRN without
an effect on postsynaptic membrane properties in an in vitro
thalamic slice preparation (Turner and Salt, 2003), indicative of a
presynaptic mechanism of action. Taken together, these results
indicate that astrocytic mGlu2 receptors act to modulate sensory-
evoked inhibition in the VB via a mechanism independent of a
direct effect on the postsynaptic neuron, and is therefore likely a
presynaptic mechanism acting to reduce inhibitory synaptic
transmission from the TRN to the VB. Indeed, astrocytes have been
shown to release adenosine, which can lead to the opening of
neuronal potassium channels (Winder et al., 1996) and subsequent
modulation of neuronal excitability and action potential propaga-
tion. This mechanism of astrocyte-neuron signalling would thus
reduce calcium inﬂux at the TRN terminal and subsequent vesicle
fusion with the presynaptic membrane. Such a non-neuronal
dependent component of synaptic transmission could be occur-
ring upon activation of astrocytic mGlu2 receptors (Fig. 6).
We are also able to infer that there is an mGlu3 receptor
component to the overall Group II mGlu receptor activity on
reducing inhibitory synaptic transmission at the TRN-VB synapse:
when examining the in vivo electrophysiological data, whilst the
selective glial inhibitor ﬂuorocitrate was able to eliminate the
mGlu2 PAM effect on sensory-evoked inhibition in the VB, there
was a remaining Group II orthosteric agonist effect, indicative of anmGlu3 receptor component likely mediated by neuronal mecha-
nisms. Indeed, there is anatomical evidence that mGlu3, but not
mGlu2, receptors are located on TRN terminals within the VB
(Tamaru et al., 2001), and that they are able to increase responses to
sensory stimulation via a reduction in inhibition arising from the
TRN (Turner and Salt, 2003). The function of these presynaptic
mGlu3 receptors, which inhibit GABAergic transmission from the
TRN by increasing Kþ conductance (Alexander and Godwin, 2006;
Cox and Sherman, 1999), is opposite to that of Group I mGlu re-
ceptors (mGlu1 & mGlu5), which depolarise TRN neurons by
decreasing Kþ conductance (Cox and Sherman,1999) and activating
a Ca2þ-dependent non-selective cation conductance (Neyer et al.,
2016). This duality in glutamatergic signalling would suggest a
state-dependent reciprocal role of glutamate within the VB-TRN
complex, which may act in concert to support complex behav-
iours. It is important to note that there is also evidence from ul-
trastructural studies that indicate both Group II mGlu receptors
may be localised on glial processes surrounding the TRN-VB syn-
apse (Ralston, 1983; Ohara and Lieberman, 1993; Liu et al., 1998;
Mineff and Valtschanoff, 1999). However, due to a lack of
commercially available mGlu3 selective ligands, we are unable to
investigate whether there is an mGlu3 astrocytic component to the
overall Group II mGlu receptor effect on sensory-evoked inhibition
in the VB.
5. Conclusions
In conclusion, our ﬁndings, at the cellular and network levels,
provide causal support for the hypothesis that mGlu2 receptor
modulation of the TRN-VB synapse is astrocyte dependent. This is
the ﬁrst evidence that mGlu2 receptors are able to activate astro-
cytes, and represents a tripartite signalling pathway that modulates
sensory processing in the thalamus. The TRN is responsible for
ensuring synchronous activity across almost all functional modal-
ities (Pinault, 2004) through inhibitory and disinhibitory circuits.
Modulation of thalamic inhibitory processing via this novel
astrocyte-dependent mechanism therefore represents an integral
component of thalamic function thought to be of importance in the
control of sensory discriminative processes (Copeland et al., 2012).
This mechanism likely functions within thalamic circuitry to enable
relevant information to be discerned from background activity, and
would thus also be important in the understanding of synaptic
processes underlying attention and cognition. This mechanismmay
therefore be an important potential therapeutic target in conditions
where perturbed inhibitory systems have been hypothesised as
contributory factors, such as in epilepsy and schizophrenia
(Huguenard, 1999; Rub et al., 2003; Barbas and Zikopoulos, 2007;
Pinault, 2011).
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